Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00781937 · ClinicalTrials.gov registry record · Phase 3
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 422
- Enrollment target
NCT00781937: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT00781937 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 422 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00781937, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 422 participants
- Enrollment target
Study Summary
This trial is conducted in North America. The aim of this clinical trial is to evaluate the potential of liraglutide to maintain long term weight loss in obese non-diabetic subjects, as well as in overweight subjects who have medical problems such as hypertension (high blood pressure) or dyslipidaemia (an abnormal amount of lipids in the blood). Trial has following trial periods: A 12-week run-in period (from week -12 to week 0) followed by a 56-week main trial period (weeks 0-56) and a 12-week follow-up period (weeks 56-68).
Primary Outcome
Subjects were weighed having fasted (consumed only water) since midnight the night before the visit.
Interventions
- DRUG placebo
- DRUG liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 422 participants |
| Start Date | 2008-10-30 |
| Est. Completion | 2010-09-01 |
| Phase | Phase 3 |
What the finished NCT00781937 record still lists
NCT00781937 is an interventional study that assigns participants to a tested intervention. The registered 422 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00781937 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00781937 about?
NCT00781937 is a clinical study titled "Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance". This trial is conducted in North America. The aim of this clinical trial is to evaluate the potential of liraglutide to maintain long term weight loss in obese non-diabetic subjects, as well as in overweight subjects who have medical problems such as hypertension (high blood pressure) or dyslipidaem...
What is the current status of trial NCT00781937?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 422 participants. The study started on 2008-10-30. Estimated completion is 2010-09-01.
What interventions are being tested in trial NCT00781937?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG).
Who is sponsoring clinical trial NCT00781937?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00781937's enrollment target sits among peer trials
422 886th of 2000 higher than 1,111 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04763356 · 422 participants · NA
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
- NCT06837246 · 422 participants · NA
A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population
- NCT07298967 · 422 participants · NA
ORCHARDS-AIR Study
- NCT06935591 · 423 participants · NA
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI